Premium
Can Open‐Source Drug R&D Repower Pharmaceutical Innovation?
Author(s) -
Munos B
Publication year - 2010
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2010.26
Subject(s) - clinical pharmacology , pharmaceutical industry , open innovation , business , pharmacology , open source , public relations , medicine , political science , marketing , computer science , software , programming language
Open‐source R&D initiatives are multiplying across biomedical research. Some of them—such as public–private partnerships—have achieved notable success in bringing new drugs to market economically, whereas others reflect the pharmaceutical industry's efforts to retool its R&D model. Is open innovation the answer to the innovation crisis? This Commentary argues that although it may likely be part of the solution, significant cultural, scientific, and regulatory barriers can prevent it from delivering on its promise. Clinical Pharmacology & Therapeutics (2010) 87 5, 534–536. doi: 10.1038/clpt.2010.26